Clinical Trial Update: Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing Spondylitis [Phase 2, Phase 3]

View source ↗

Summary

Open-label phase 2/3 trial evaluating rituximab (MabThera) in ankylosing spondylitis; status is not specified in the document.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• MabThera (rituximab)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Ankylosing Spondylitis | Phase 2, Phase 3 | Status: UNKNOWN